Icecure Medical Ltd ICCM
News
IceCure Expands ProSense® ChoICE Study for Low-Risk Breast Cancer adding Legacy Health in Portland, OR as U.S. Clinical Site
IceCure Medical Receives Regulatory Approval to Market ProSense® in China
IceCure Signs Exclusive Distribution Agreement for ProSense® Cryoablation Systems in the Netherlands
West Cancer Center Receives IRB Approval to Commence IceCure's ChoICE Study for Breast Cancer Cryoablation
IceCure Highlights Two New Peer-Reviewed Publications Supporting Cryoablation in Breast Cancer Treatment De-Escalation
IceCure Reports its Financial Results for the First Half of 2026 with 45% Revenue Growth Year-Over-Year
IceCure Medical Adds Adventist Health as U.S. Clinical Site for its Post-Marketing "ChoICE" Study for Low-Risk Breast Cancer Cryoablation Treatment
IceCure Medical to Report First Half 2026 Financial and Operating Results on August 12, 2026
IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance of ProSense®
IceCure Medical Kicks Off its Post-Marketing "ChoICE" Study for the Low-Risk Breast Cancer Treatment at First U.S Clinical Site
